The Promise of Induced Pluripotent Stem Cells in the Biomedical Research 2.0
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 2121
Special Issue Editor
Interests: induced pluripotent stem cells; McArdle disease; mitochondrial disorders; modeling disorders; CRISPR/Cas9; drug repurposing studies; tissue engineering
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
More than a decade ago, the Japanese scientist Shinya Yamanaka showed that it is possible to convert adult cells into a state similar to that of pluripotent stem cell. These cells, named induced pluripotent stem cells (iPSCs), are similar to embryonic stem cells (ES) and are considered a very promising tool in the field of regenerative medicine. iPSCs, like ES cells, are self-renewing and pluripotent. Furthermore, because iPSCs are obtained from adult cells in vitro, they do not raise the ethical and legal problems associated with the use of ES cells. Because they are generated from the patient, the likelihood of rejection in autologous therapies is believed to be much lower. This Special Issue will address the applications of iPSCs, putting a special emphasis on the investigation of the physiopathogenic mechanisms behind diseases and the search for new therapies against them. Therefore, contributions by experts in the field, in the form of original articles and reviews, are most welcome.
Dr. M. Esther Gallardo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- induced pluripotent stem cells
- drug discovery
- cell modelling
- cell therapy
- personalized medicine
- tissue engineering
